Literature DB >> 33355094

Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study.

Alex S Bennett1,2, Robert Freeman3, Don C Des Jarlais1,2,4, Ian David Aronson1,2.   

Abstract

BACKGROUND: Many people use opioids and are at risk of overdose. Naloxone is an opioid antagonist used to counter the effects of opioid overdose. There is an increased availability of naloxone in New York City; however, many who use opioids decline no-cost naloxone even when offered. Others may have the medication but opt not to carry it and report that they would be reluctant to administer it if they were to witness an overdose.
OBJECTIVE: We aim to better understand why people who use opioids may be reluctant to accept, carry, and administer naloxone, and to inform the development of messaging content that addresses barriers to its acceptance and use.
METHODS: We conducted formative qualitative interviews with 20 people who use opioids who are 18 years and older in New York City. Participants were recruited via key informants and chain referral.
RESULTS: Participants cited 4 main barriers that may impede rates of naloxone acceptance, possession, and use: (1) stigma related to substance use, (2) indifference toward overdose, (3) fear of negative consequences of carrying naloxone, and (4) fear of misrecognizing the need for naloxone. Participants also offered suggestions about messaging content to tackle the identified barriers, including messages designed to normalize naloxone possession and use, encourage shared responsibility for community health, and elicit empathy for people who use drugs. Taken together, participants' narratives hold implications for the following potential messaging content: (1) naloxone is short-acting, and withdrawal sickness does not have to be long-lasting; (2) it is critical to accurately identify an opioid-involved overdose; (3) anyone can overdose; (4) naloxone cannot do harm; and (5) the prompt administration of the medication can help ensure that someone can enjoy another day. Finally, participants suggested that messaging should also debunk myths and stereotypes about people who use drugs more generally; people who use opioids who reverse overdoses should be framed as lay public health advocates and not just "others" to be managed with stigmatizing practices and language.
CONCLUSIONS: It must be made a public health priority to get naloxone to people who use opioids who are best positioned to reverse an overdose, and to increase the likelihood that they will carry naloxone and use it when needed. Developing, tailoring, and deploying messages to address stigma, indifference toward overdose, fear and trepidation about reversing an overdose, and fear of police involvement may help alleviate fears among some people who are reluctant to obtain naloxone and use the medication on someone in an overdose situation. ©Alex S Bennett, Robert Freeman, Don C Des Jarlais, Ian David Aronson. Originally published in JMIR Formative Research (http://formative.jmir.org), 23.12.2020.

Entities:  

Keywords:  harm reduction; messaging; naloxone; opioids; overdose; people who use opioids; public health intervention

Year:  2020        PMID: 33355094      PMCID: PMC7787889          DOI: 10.2196/22411

Source DB:  PubMed          Journal:  JMIR Form Res        ISSN: 2561-326X


  38 in total

1.  Expanded access to opioid overdose intervention: research, practice, and policy needs.

Authors:  Wilson M Compton; Nora D Volkow; Douglas C Throckmorton; Peter Lurie
Journal:  Ann Intern Med       Date:  2013-01-01       Impact factor: 25.391

2.  From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA.

Authors:  Alex S Bennett; Alice Bell; Maya Doe-Simkins; Luther Elliott; Enrique Pouget; Corey Davis
Journal:  J Psychoactive Drugs       Date:  2018-02-09

3.  "I Gotta Go With Modern Technology, So I'm Gonna Give 'em the Narcan": The Diffusion of Innovations and an Opioid Overdose Prevention Program.

Authors:  Jeanette M Bowles; Stephen E Lankenau
Journal:  Qual Health Res       Date:  2018-10-12

4.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

5.  Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA.

Authors:  Sarah Bessen; Stephen A Metcalf; Elizabeth C Saunders; Sarah K Moore; Andrea Meier; Bethany McLeman; Olivia Walsh; Lisa A Marsch
Journal:  Int J Drug Policy       Date:  2019-10-04

6.  Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths.

Authors:  Jessica Rando; Derek Broering; James E Olson; Catherine Marco; Stephen B Evans
Journal:  Am J Emerg Med       Date:  2015-05-29       Impact factor: 2.469

7.  Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention.

Authors:  Harshal Kirane; Michael Ketteringham; Sewit Bereket; Richie Dima; Ann Basta; Sonia Mendoza; Helena Hansen
Journal:  J Subst Abuse Treat       Date:  2016-07-18

8.  "Generally, you get 86'ed because you're a liability": An application of Integrated Threat Theory to frequently witnessed overdoses and social distancing responses.

Authors:  J M Bowles; L R Smith; S R Verdugo; K D Wagner; P J Davidson
Journal:  Soc Sci Med       Date:  2020-07-09       Impact factor: 4.634

Review 9.  A systematic review of community opioid overdose prevention and naloxone distribution programs.

Authors:  Angela K Clark; Christine M Wilder; Erin L Winstanley
Journal:  J Addict Med       Date:  2014 May-Jun       Impact factor: 3.702

Review 10.  Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.

Authors:  Todd Kerensky; Alexander Y Walley
Journal:  Addict Sci Clin Pract       Date:  2017-01-07
View more
  11 in total

1.  Businesses in high drug use areas as potential sources of naloxone during overdose emergencies.

Authors:  Kristin E Schneider; Saba Rouhani; Noelle P Weicker; Miles Morris; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2022-02-17       Impact factor: 4.492

2.  Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.

Authors:  Justin C Strickland; Katherine R Marks; Kirsten E Smith; Jennifer D Ellis; J Gregory Hobelmann; Andrew S Huhn
Journal:  Int J Drug Policy       Date:  2022-05-26

Review 3.  U.S. Military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts.

Authors:  Alex S Bennett; Honoria Guarino; Peter C Britton; Dan O'Brien-Mazza; Stephanie H Cook; Franklin Taveras; Juan Cortez; Luther Elliott
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

4.  Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.

Authors:  Sean Grant; Rosanna Smart
Journal:  Harm Reduct J       Date:  2022-06-08

Review 5.  Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.

Authors:  Alex S Bennett; Luther Elliott
Journal:  Transl Res       Date:  2021-03-05       Impact factor: 10.171

6.  How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study.

Authors:  Ian David Aronson; Alex S Bennett; Mary-Andrée Ardouin-Guerrier; German Rivera-Castellar; Brent Gibson; Samantha Santoscoy; Brittney Vargas-Estrella
Journal:  JMIR Form Res       Date:  2022-03-23

7.  Naloxone prescribing practices in the Military Health System before and after policy implementation.

Authors:  Jennifer Pakieser; Sidney Peters; Laura C Tilley; Ryan C Costantino; Maya Scott-Richardson; Krista B Highland
Journal:  Pain Rep       Date:  2021-03-14

8.  Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.

Authors:  Alex S Bennett; Joy Scheidell; Jeanette M Bowles; Maria Khan; Alexis Roth; Lee Hoff; Christina Marini; Luther Elliott
Journal:  Harm Reduct J       Date:  2022-03-04

9.  A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.

Authors:  Antoinette L Spector; Carol L Galletly; Erika A Christenson; H Danielle Green Montaque; Julia Dickson-Gomez
Journal:  BMC Public Health       Date:  2022-07-19       Impact factor: 4.135

Review 10.  The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy.

Authors:  Ali Cheetham; Louisa Picco; Anthony Barnett; Dan I Lubman; Suzanne Nielsen
Journal:  Subst Abuse Rehabil       Date:  2022-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.